According to Supernus Pharmaceuticals
's latest financial reports the company has a price-to-book ratio of 2.80368.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2025-12-31 | N/A | -100% |
2024-12-31 | 1.98 | 15.53% |
2023-12-31 | 1.72 | -21.15% |
2022-12-31 | 2.18 | 14.47% |
2021-12-31 | 1.90 | 6.44% |
2020-12-31 | 1.79 | -14.67% |
2019-12-31 | 2.09 | -45.45% |
2018-12-31 | 3.84 | -49.77% |
2017-12-31 | 7.64 | 17.08% |
2016-12-31 | 6.52 | -12.83% |
2015-12-31 | 7.48 | -14.61% |
2014-12-31 | 8.76 | -2.72% |
2013-12-31 | 9.01 | 136.22% |
2012-12-31 | 3.81 | |
2011-12-31 | N/A | |
2010-12-31 | N/A | |
2009-12-31 | N/A |
Company | P/B ratio | P/B ratio differencediff. | Country |
---|---|---|---|
![]() United Therapeutics UTHR | 1.97 | 8.51% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | 43.2 | 2,278.68% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 5.47 | 200.80% | ๐บ๐ธ USA |
![]() Abbott Laboratories ABT | 4.54 | 149.82% | ๐บ๐ธ USA |
![]() Johnson & Johnson JNJ | 5.18 | 185.26% | ๐บ๐ธ USA |